CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, announced that it will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) and the NASDAQ-100 Ex-Tech Sector Index (Nasdaq: NDXX) prior to market open on Monday, July 20, 2020.

The NASDAQ-100 includes the 100 largest non-financial companies listed on the Nasdaq Stock Market, based on market capitalization. The Index is heavily concentrated with technology companies and the next largest sectors include consumer services, healthcare, industrials and telecommunications.

Moderna’s common stock began trading on The Nasdaq Global Select Market on December 7, 2018.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients and to protect populations from vaccines preventable diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. (Read more…) Department of Defense, and Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.

Contacts

Moderna


Media:
Colleen Hussey

Senior Manager, Corporate Communications

203-470-5620

[email protected]

Investors:
Lavina Talukdar

Head of Investor Relations

617-209-5834

[email protected]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, announced that it will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) and the NASDAQ-100 Ex-Tech Sector Index (Nasdaq: NDXX) prior to market open on Monday, July 20, 2020.

The NASDAQ-100 includes the 100 largest non-financial companies listed on the Nasdaq Stock Market, based on market capitalization. The Index is heavily concentrated with technology companies and the next largest sectors include consumer services, healthcare, industrials and telecommunications.

Moderna’s common stock began trading on The Nasdaq Global Select Market on December 7, 2018.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients and to protect populations from vaccines preventable diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. (Read more…) Department of Defense, and Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.

Contacts

Moderna


Media:
Colleen Hussey

Senior Manager, Corporate Communications

203-470-5620

[email protected]

Investors:
Lavina Talukdar

Head of Investor Relations

617-209-5834

[email protected]